Beqvez access in Qatar: the MOPH-PD named-patient pathway
How patients in the State of Qatar legally obtain Beqvez (fidanacogene elaparvovec-dzkt) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Quick orientation
Patients in Qatar access Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe haemophilia B in adults who are FIX-inhibitor negative and have neutralising anti-AAVRh74var antibody status below the assay cutoff through the MOPH-PD named-patient pathway, a the Pharmacy and Drug Control Department of the Qatar Ministry of Public Health-administered mechanism that allows a Qatari-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in QAR.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Reserved for you.
Why Qatari patients need Beqvez through the named-patient pathway
The State of Qatar operates a structured pharmaceutical regulatory environment. Beqvez (fidanacogene elaparvovec-dzkt) is regulated through MOPH-PD (the Pharmacy and Drug Control Department of the Qatar Ministry of Public Health) channels, and a Qatari family asking for Beqvez is rarely asking for a medicine that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to.
Four converging patterns drive these cases. First, indication lag. Beqvez's newer FDA-approved indications and dosing expansions often reach local registration 12 to 36 months after the US label. A family whose treating physician has documented a clear FDA-label fit may still find that the local label has not caught up. Second, presentation gaps. The exact strength, weight-banded dose, or pen format the prescriber needs may not be stocked at the local agent even when the medicine is registered. Third, payer denial. Hamad Medical Corporation public coverage, QLM, and GIG Gulf Qatar each assess specialty therapies case by case, and step-therapy or formulary rules often produce denials even when the drug is on the local register. Cash-pay families pursue cross-border supply rather than wait through appeals. Fourth, continuity of supply. When a US-stable patient relocates to Qatar or visits family for an extended period, maintaining the original FDA-sourced regimen matters more than switching to a different local presentation.
In each pattern, the MOPH-PD named-patient pathway is the mechanism that connects a Qatari-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient. Clinically, Beqvez is a one-time adeno-associated virus serotype Rh74var (AAVRh74var) gene therapy delivering a high-activity factor IX variant (FIX-Padua, R338L) transgene to hepatocytes via a liver-tropic capsid, enabling durable endogenous FIX production, and the named-patient route preserves that mechanism rather than substituting a non-equivalent local option.
Current regulatory status of Beqvez in Qatar
The Ministry of Public Health, Department of Pharmacy and Drug Control (وزارة الصحة العامة - إدارة الصيدلة ومراقبة الدواء; MOPH / DPDC) is the Qatar medicines regulator under Qatar Law No. 3 of 1983 regulating the practice of pharmacy professions and pharmaceutical establishments and the trade of pharmaceuticals. Source: MOPH Qatar.
Beqvez (fidanacogene elaparvovec-dzkt; Pfizer) is a one-time adeno-associated virus serotype Rh74var (AAVRh74var) gene therapy delivering a high-activity factor IX-Padua (R338L) variant transgene to hepatocytes. FDA approval was granted in 2024 for adults with moderate-to-severe haemophilia B who are FIX-inhibitor negative and have neutralising anti-AAVRh74var antibody titre below the assay cutoff. As of 2026-05-31, no public MOPH record of a Qatar marketing authorisation for fidanacogene elaparvovec has been observed.
Cross-border access proceeds through the MOPH Department of Pharmacy and Drug Control as a compassionate-use named-patient file. The file specifies the haemophilia B genetic confirmation, factor IX activity at baseline, FIX-inhibitor status (negative on consecutive Bethesda assays), neutralising anti-AAVRh74var antibody titre (below cutoff), prior FIX-product history, and the dosing plan (single weight-banded IV infusion of 5 x 10^11 vg/kg).
The post-infusion monitoring regimen for AAV gene therapy is substantial: weekly liver-function testing for at least the first 26 weeks (corticosteroid taper if ALT rises), serial FIX activity monitoring, and immunosuppression management. The file specifies the post-infusion monitoring plan.
Last verified by ARCH-74: 2026-05-31.
Named tertiary centres in Qatar where Beqvez is dispensed
Fidanacogene elaparvovec is an adult haematology gene therapy; the indication restricts dispensing to adult haematology centres with documented gene-therapy infusion capability. In Qatar:
- Hamad Medical Corporation - National Center for Cancer Care and Research (NCCCR), Doha - Department of Haematology / Bone Marrow Transplant Programme; the principal adult haematology centre with gene-therapy infrastructure for inhibitor-screened haemophilia B patients. Source: NCCCR / HMC.
- Hamad General Hospital, Doha - Department of Internal Medicine / Haematology; routine haemophilia outpatient care.
- Sidra Medicine, Doha - paediatric haematology (the Beqvez indication is adult-only; Sidra is not a dispensing centre for this drug, but cross-referral from paediatric haematology to adult NCCCR for post-18 transition cases is the established pattern). Source: Sidra Medicine.
- Al-Ahli Hospital, Doha - private tertiary with haematology service for insurance and expatriate cases.
The gene-therapy infusion centre, the cold-chain handling of the gene-therapy product (frozen storage and timed thaw-and-infuse window), and the post-infusion immunosuppression workflow concentrate this drug at NCCCR. Other Qatari centres do not currently maintain the operational pathway for a one-time AAV gene therapy of this complexity.
Local pricing reference for Beqvez in Qatar
US WAC reference for Beqvez (fidanacogene elaparvovec, one-time IV infusion of 5 x 10^11 vg/kg) is approximately USD 3,500,000 per dose at the US list price. This is a single-administration product; there is no annualised reuse. Source: Beqvez FDA Prescribing Information; Pfizer public statements on Beqvez pricing.
No public QAR reference price for fidanacogene elaparvovec has been observed on MOPH or HMC published lists as of 2026-05-31. QAR is pegged to USD at approximately 3.64 QAR per USD; the indicative QAR per-dose reference is approximately QAR 12.7 million. Source: Qatar Central Bank.
Price snapshot date: 2026-05-31. The drug cost is the dominant cost line; post-infusion monitoring (weekly LFTs for 26 weeks plus, factor IX assays, immunosuppression including potential corticosteroid taper) is locally sourced through NCCCR and is a separate, materially smaller cost line.
Country-specific access barriers for Beqvez in Qatar
The principal access pattern in Qatar for fidanacogene elaparvovec is the HMC funding-and-clinical pathway. Qatari nationals with adult haemophilia B receive specialty care through HMC at no or low cost; the National Cancer Program and Qatar Genome Programme provide adjacent infrastructure. The HMC haematology service evaluates gene-therapy candidacy on a case-by-case basis; eligibility involves the FIX-inhibitor screen, the neutralising anti-AAV antibody titre, and the post-infusion monitoring commitment.
For Qatari nationals the cost is typically absorbed through HMC's high-cost-medicine budget; this is a finite resource and prioritisation considerations apply. For expatriates (approximately 88% of the Qatar population per Planning and Statistics Authority), funding shifts to employer-sponsored private insurance (QLM, AXA Gulf Qatar, Daman, Allianz Care, Bupa Global) where coverage of a one-time gene therapy at this cost band is policy-specific and typically requires substantial documented justification; or to self-pay.
For Qatari-resident expatriate haemophilia B patients seeking the drug, the operational route customarily anchors on HMC NCCCR as the dispensing centre even where funding is private; HMC's gene-therapy infusion infrastructure is the principal Qatar-side enabler.
Cold-chain logistics for AAV gene therapy are frozen-storage and timed-thaw; Doha airport handles frozen biological clearance routinely through HMC's specialty-medicine logistics partners. The anti-AAVRh74var-antibody pre-screen is a binding eligibility criterion - the file is not submitted before the screen confirms titre below the assay cutoff.
Recent local regulatory news touching Beqvez or its drug class in Qatar
No MOPH bulletin specifically naming fidanacogene elaparvovec or the AAV-mediated haemophilia-B gene-therapy class has been observed in the last twelve months on the MOPH media centre as of 2026-05-31. Adjacent context:
- FDA approval of fidanacogene elaparvovec in 2024 is the recent regulatory event; class-level long-term-durability data continues to accumulate and FDA labelling will iterate. Source: FDA Drugs@FDA database.
- Qatar Genome Programme and the National Cancer Program continue to coordinate on rare-disease and inherited-disorder gene-therapy capacity-building; HMC is the principal operational partner. Source: Qatar Genome Programme.
What your physician needs to provide
For a Qatari-licensed specialist prescribing Beqvez through the MOPH-PD pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's confirmed diagnosis for moderate to severe haemophilia B in adults who are FIX-inhibitor negative and have neutralising anti-AAVRh74var antibody status below the assay cutoff, severity assessment (scoring instrument, biomarker, imaging, or biopsy as appropriate for the indication), prior therapy history including first-line options tried, and a clinical rationale for why Beqvez is the appropriate next step given a one-time adeno-associated virus serotype Rh74var (AAVRh74var) gene therapy delivering a high-activity factor IX variant (FIX-Padua, R338L) transgene to hepatocytes via a liver-tropic capsid, enabling durable endogenous FIX production.
The letter also specifies the exact dosing plan per the FDA-approved label: starting dose, maintenance dose, route of administration, schedule, and intended duration of therapy. Monitoring plan should reference any baseline laboratory or imaging requirements specific to Beqvez (full blood count, liver function, infection screen, ophthalmology assessment, or pregnancy testing where the FDA label requires it), planned follow-up intervals, and dose-modification criteria for the most common adverse events.
The treating physician's Qatari license number, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. For cold-chain or specialty-handling products, the dispensing pharmacy's documented storage protocol and continuous-temperature-monitoring log are part of the chain-of-custody record we share with the importer.
Common questions about Beqvez in Qatar
Will Hamad Medical Corporation public coverage, QLM, and GIG Gulf Qatar cover this? Each insurer assesses named-patient imports case by case. Some reimburse fully when Beqvez is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.
Is the FDA-approved indication recognised by MOPH-PD? The MOPH-PD named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; MOPH-PD review focuses on the clinical justification rather than re-litigating the FDA decision.
My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine? Any Qatari-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. Qatar Council for Healthcare Practitioners (QCHP) and the MOPH verifies the active license; the MOPH-PD application records both the prescribing physician and the dispensing facility.
Can I receive Beqvez at home? The dispensing facility must be Qatari-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.
What about competitors or alternative therapies in the same class? Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.
Where Reserve Meds fits in Beqvez cases
Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace MOPH-PD, and we do not replace your dispensing pharmacy. For Beqvez specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Qatar, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.
Operationally, a typical Beqvez case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the MOPH-PD application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.
Beqvez is a single-dose intravenous gene therapy delivered at a certified Treatment Centre; pre-screening for AAVRh74var neutralising antibodies, baseline liver health, and the post-infusion immunosuppression and ALT-monitoring schedule are mandatory.
Next step
If your Qatari physician has prescribed Beqvez and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.